Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2008

01-04-2008 | Brief Report

The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge

Authors: J.-J. Yu, E. K. Raulie, A. K. Murthy, M. N. Guentzel, K. E. Klose, B. P. Arulanandam

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2008

Login to get access

Excerpt

Francisella tularensis is a gram-negative, facultative intracellular bacterium and is the causative agent of the zoonotic disease tularemia [1]. F. tularensis has been considered a potential biological weapon due to its low infectious dose and high mortality rate [2]. F. tularensis can be classified into several subspecies, including those relevant to human disease: F. tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type B); F. novicida and F. mediasiatica [3]. However, most of our knowledge about the pathogenesis of Francisella and the immune responses to the infection have come from studies of F. tularensis LVS (derived from holartica) and F. novicida [46]. Both organisms are attenuated in humans, while retaining virulence in mice. It is well established that Francisella enters and replicates within host cells, and a strong research focus has been on deciphering the mechanisms for intramacrophage growth. However, little is known about the extracellular phase of Francisella. F. tularensis has been cultured from blood of infected animals and humans, although the reported cases have been rare [7, 8]. Specifically, Long et al. [8] demonstrated that LVS could be recovered from plasma prepared from mice 72 h after intravenous infection. These extracellular bacteria accounted for less than 1% of total LVS within the blood. However, a recent study by Forestal et al. [9] indicated a much higher percentage (>50%) of extracelluar Francisella (type A SCHU S4 and LVS) within plasma of mice infected intradermally or intranasally. Here, independently, we confirm the presence of extracellular Francisella in plasma after intranasal F. novicida challenge in a murine model of pulmonary tularemia [6]. Moreover, we demonstrate that the extracellular Francisella in plasma is highly infectious and that this phase may contribute to the rapid dissemination of the bacterium from lungs to the liver after pulmonary infection. …
Literature
1.
go back to reference Tarnvik A (1989) Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11:440–451PubMed Tarnvik A (1989) Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11:440–451PubMed
2.
go back to reference Dennis DT, Inglesby TV, Henderson DA et al (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285:2763–2773PubMedCrossRef Dennis DT, Inglesby TV, Henderson DA et al (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285:2763–2773PubMedCrossRef
3.
go back to reference Titball RW, Johansson A, Forsman M (2003) Will the enigma of Francisella tularensis virulence soon be solved? Trends Microbiol 11:118–123PubMedCrossRef Titball RW, Johansson A, Forsman M (2003) Will the enigma of Francisella tularensis virulence soon be solved? Trends Microbiol 11:118–123PubMedCrossRef
4.
go back to reference Elkins KL, Cowley SC, Bosio CM (2003) Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect 5:135–142PubMedCrossRef Elkins KL, Cowley SC, Bosio CM (2003) Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect 5:135–142PubMedCrossRef
5.
go back to reference Lauriano CM, Barker JR, Yoon SS, Nano FE, Arulanandam BP, Hassett DJ, Klose KE (2004) MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc Natl Acad Sci USA 101:4246–4249PubMedCrossRef Lauriano CM, Barker JR, Yoon SS, Nano FE, Arulanandam BP, Hassett DJ, Klose KE (2004) MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc Natl Acad Sci USA 101:4246–4249PubMedCrossRef
6.
go back to reference Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP (2006) Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun 74:2063–2071PubMedCrossRef Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP (2006) Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun 74:2063–2071PubMedCrossRef
7.
go back to reference Provenza MJ, Klotz SA, Penn RL (1986) Isolation of Francisella tularensis from blood. J Clin Microbiol 24:453–455PubMed Provenza MJ, Klotz SA, Penn RL (1986) Isolation of Francisella tularensis from blood. J Clin Microbiol 24:453–455PubMed
8.
go back to reference Long GW, Oprandy JJ, Narayanan RB, Fortier AH, Porter KR, Nacy CA (1993) Detection of Francisella tularensis in blood by polymerase chain reaction. J Clin Microbiol 31:152–154PubMed Long GW, Oprandy JJ, Narayanan RB, Fortier AH, Porter KR, Nacy CA (1993) Detection of Francisella tularensis in blood by polymerase chain reaction. J Clin Microbiol 31:152–154PubMed
9.
go back to reference Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, Sellati TJ, Furie MB (2007) Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis 196:134–137PubMedCrossRef Forestal CA, Malik M, Catlett SV, Savitt AG, Benach JL, Sellati TJ, Furie MB (2007) Francisella tularensis has a significant extracellular phase in infected mice. J Infect Dis 196:134–137PubMedCrossRef
10.
go back to reference Forsman M, Sandstrom G, Sjostedt A (1994) Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of the phylogeny of the genus and for identification of strains by PCR. Int J Syst Bacteriol 44:38–46PubMedCrossRef Forsman M, Sandstrom G, Sjostedt A (1994) Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of the phylogeny of the genus and for identification of strains by PCR. Int J Syst Bacteriol 44:38–46PubMedCrossRef
11.
go back to reference Edelson BT, Unanue ER (2001) Intracellular antibody neutralizes Listeria growth. Immunity 14:503–512PubMedCrossRef Edelson BT, Unanue ER (2001) Intracellular antibody neutralizes Listeria growth. Immunity 14:503–512PubMedCrossRef
12.
go back to reference Li JS, Winslow GM (2003) Survival, replication, and antibody susceptibility of Ehrlichia chaffeensis outside of host cells. Infect Immun 71:4229–4237PubMedCrossRef Li JS, Winslow GM (2003) Survival, replication, and antibody susceptibility of Ehrlichia chaffeensis outside of host cells. Infect Immun 71:4229–4237PubMedCrossRef
13.
go back to reference Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179:532–539PubMed Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179:532–539PubMed
14.
go back to reference Stenmark S, Lindgren H, Tarnvik A, Sjostedt A (2003) Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog 35:73–80PubMedCrossRef Stenmark S, Lindgren H, Tarnvik A, Sjostedt A (2003) Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog 35:73–80PubMedCrossRef
Metadata
Title
The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge
Authors
J.-J. Yu
E. K. Raulie
A. K. Murthy
M. N. Guentzel
K. E. Klose
B. P. Arulanandam
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0434-x

Other articles of this Issue 4/2008

European Journal of Clinical Microbiology & Infectious Diseases 4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine